Literature DB >> 33374356

Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System.

Courtney M Barkoff1, Shaker A Mousa1.   

Abstract

Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.

Entities:  

Keywords:  C3; C5; COVID-19; SARS-CoV-2; coagulopathy; complement; compstatin; heparin; inflammation

Year:  2020        PMID： 33374356      PMCID： PMC7823480          DOI： 10.3390/biomedicines9010011

Source DB:  PubMed          Journal:  Biomedicines        ISSN： 2227-9059


  45 in total

1.  Mechanism of action and pharmacology of unfractionated heparin.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

2.  Transfusion-associated circulatory overload after plasma transfusion.

Authors:  Christina Narick; Darrell J Triulzi; Mark H Yazer
Journal:  Transfusion       Date:  2011-07-18       Impact factor: 3.157

Review 3.  Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Authors:  Magdalena Riedl; Fadi Fakhouri; Moglie Le Quintrec; Damien G Noone; Therese C Jungraithmayr; Veronique Fremeaux-Bacchi; Christoph Licht
Journal:  Semin Thromb Hemost       Date:  2014-06-09       Impact factor: 4.180

4.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.

Authors:  M D Kazatchkine; D T Fearon; D D Metcalfe; R D Rosenberg; K F Austen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

5.  Treating COVID-19 with Chloroquine.

Authors:  Mingxing Huang; Tiantian Tang; Pengfei Pang; Man Li; Ruolan Ma; Jiahui Lu; Jingxian Shu; Yingying You; Binghui Chen; Jiabi Liang; Zhongsi Hong; Huili Chen; Ling Kong; Dajiang Qin; Duanqing Pei; Jinyu Xia; Shanping Jiang; Hong Shan
Journal:  J Mol Cell Biol       Date:  2020-05-18       Impact factor: 6.216

6.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Authors:  Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie
Journal:  BMJ       Date:  2020-05-14

7.  The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.

Authors:  Sara Mastaglio; Annalisa Ruggeri; Antonio M Risitano; Piera Angelillo; Despina Yancopoulou; Dimitrios C Mastellos; Markus Huber-Lang; Simona Piemontese; Andrea Assanelli; Cecilia Garlanda; John D Lambris; Fabio Ciceri
Journal:  Clin Immunol       Date:  2020-04-29       Impact factor: 3.969

8.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

9.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

10.  Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.

Authors:  Dimitrios C Mastellos; Bruno G P Pires da Silva; Benedito A L Fonseca; Natasha P Fonseca; Maria Auxiliadora-Martins; Sara Mastaglio; Annalisa Ruggeri; Marina Sironi; Peter Radermacher; Akrivi Chrysanthopoulou; Panagiotis Skendros; Konstantinos Ritis; Ilenia Manfra; Simona Iacobelli; Markus Huber-Lang; Bo Nilsson; Despina Yancopoulou; E Sander Connolly; Cecilia Garlanda; Fabio Ciceri; Antonio M Risitano; Rodrigo T Calado; John D Lambris
Journal:  Clin Immunol       Date:  2020-09-19       Impact factor: 3.969
View more
  1 in total

1.  Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.

Authors:  Piero Ruggenenti; Fabiano Di Marco; Monica Cortinovis; Luca Lorini; Silvia Sala; Luca Novelli; Federico Raimondi; Sara Gastoldi; Miriam Galbusera; Roberta Donadelli; Caterina Mele; Rossella Piras; Marina Noris; Valentina Portalupi; Laura Cappelletti; Camillo Carrara; Federica Tomatis; Silvia Bernardi; Annalisa Perna; Tobia Peracchi; Olimpia Diadei; Ariela Benigni; Giuseppe Remuzzi
Journal:  PLoS One       Date:  2021-12-20       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.